Tea Shehu Kolnikaj

Dr. Tea Shehu Kolnikaj

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Medicina
Verified
Journal Article
Open access
PDF file
TKTea Shehu Kolnikaj
Tea Shehu Kolnikaj
RHRok Herman
Rok Herman
Andrej JanežAndrej Janež
Andrej Janež
MJMojca Jensterle
Mojca Jensterle
Polycystic ovary syndrome (PCOS) manifests a multifactorial pathology characterized by polycystic ovaries, menstrual cycle disorders, varying degrees of hyperandrogenism, and an ad-verse metabolic risk profile. The position of hyperandrogenism in this syndrome has been extensively studied. A multitude of mechanisms place it in the position of cause but also of consequence; therefore, ongoing research efforts are focused on identifying medications that can effectively reduce levels of androgens in women with PCOS. Moreover, lipid abnormalities are common in this population, with up to 70% of patients having dyslipidemia. Statins may have potential therapeutic benefits for women with PCOS, as they have been shown to improve insulin resistance and reduce the risk of cardiovascular disease. In addition, their role in accelerated steroidogenesis by limiting one source of cholesterol, influencing enzymatic activity, and providing several other beneficial mechanisms is widely investigated. This review aimed to provide a comprehensive overview of the pathogenesis of androgen excess and dyslipidemia in PCOS, as well as the therapeutic potential of statins.

16 November 2022 in Life
Verified
Journal Article
Open access
PDF file
TKTea Shehu Kolnikaj
Tea Shehu Kolnikaj
RHRok Herman
Rok Herman
Andrej JanežAndrej Janež
Andrej Janež
MJMojca Jensterle
Mojca Jensterle
The essential role of the frequent coexistence of mental disorders and polycystic ovary syndrome (PCOS) is being increasingly recognized in the management of PCOS patients since it influences the success of weight loss interventions. Patients frequently experience disrupted eating behaviors, evidenced by the high prevalence of eating disorders in this population. Therefore, assessment and potential modification of eating disorders and eating-related behavior might be especially relevant to improve obesity treatment outcomes in this population, which remains the most efficient causal treatment in PCOS patients with high metabolic risk. Following a literature overview on common eating disorders and eating behaviors in PCOS, the aim of this review was to explore the prevalence and underlying mechanisms behind those occurrences. Understanding the clinical relevance of those associations and the addition of the assessments of eating disorders as well as eating phenotypes, eating chronotypes, and eating content as essential determinants of eating behavior could aid in the successful management of women with PCOS. In addition, the review also covers the potential of using eating disorders and eating behavior as a tool for the personalization of obesity treatment in PCOS.

1 January 2026 in Human Mutation
Verified
Journal Article
Open access
PDF file
TKTea Shehu Kolnikaj
Tea Shehu Kolnikaj
MRMaren Ruka
Maren Ruka
AXArtur Xhumari
Artur Xhumari
ABAnila Babameto-Laku
Anila Babameto-Laku
ASAthanasios Siolos
Athanasios Siolos
MKMárta Korbonits
Márta Korbonits
Familial isolated pituitary adenoma (FIPA) accounts for approximately 2%–5% of all pituitary adenomas, with inactivating variants of the aryl hydrocarbon receptor‐interacting protein ( AIP ) gene representing the most frequent known genetic cause. Clinically, patients with AIP variants often have young‐onset macroadenomas with growth hormone hypersecretion, although disease severity and penetrance are variable. Most reported AIP variants are point mutations, whereas large deletions are rare and potentially underdiagnosed. Accurate detection of AIP copy‐number variants requires methods such as multiplex ligation‐dependent probe amplification or validated copy‐number analysis of next‐generation sequencing data, as Sanger sequencing alone may fail to identify these alterations. Due to the rarity of the disease, it is unknown whether large deletions in the ubiquitously expressed AIP gene are associated with potentially more severe phenotype. Available data suggest that large deletions may occur in 8%–10% of AIP mutation‐positive pedigrees, highlighting the importance of incorporating copy‐number variant detection into AIP testing workflows. We analysed data from all published patients with large AIP deletions ( n = 25) and report here two novel large AIP deletions (Exons 3–4 and Exons 2–6 deletions) and three additional three families, including an Albanian kindred associated with metastatic Hürthle cell thyroid carcinoma. No major differences compared with other AIP variants were found in age at diagnosis, tumour size, hormonal profile, sex distribution or presence of other tumours. A role for AIP variants in thyroid carcinogenesis is unlikely.